rais compound-annual-growth-rate ep growth
increas pt old
new maintain ow rate
keytruda lot room run view project keytruda sale
ramp driven global roll-out
keytruda sever cancer plu potenti shift earlier treatment
paradigm time
rais out-year project primarili higher ex-u keytruda keytruda
chemo combo first line lung cancer start ramp ex-u
surpris learn earn call eu countri expect
final reimburs mean ex-u sale benefit
still larg front merck increas ex-u keytruda estim
ep ms
januvia face gener eu januari look forward
merck fill januvia hole intern extern pipelin candid
come year previous model ex-u gener june
model januari consist us januvia gener entri time januari
project pre-cliff global januvia sale total
fall total pipelin model reflect total
new pipelin contribut hope merck execut
extern transact enhanc pipelin prospect
see clear path greater oper leverag compound-annual-growth-rate revenue
oper incom ep project respect
forecast merck oper margin rise basi point
despit aggress invest estimate rise
expect major surpris schedul analyst day june look
forward clariti long-term busi driver merck schedul
host analyst day nyc june given exist disclosur
expect meet includ big surpris anticip addit key
product pipelin detail hope support thesi merck
solid durabl growth prospect
major pharmaceut unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
pt base base case ep target multipl
premium peer averag believ justifi
given acceler growth prospect emerg pipelin prospect
bull case ep
bull case ep
keytruda surpris upsid merck fill januvia cliff ep
forecast due higher-than-project keytruda sale drive
result merck intern pipelin surpris upsid plu add
candid off-set januvia patent cliff
base case ep
base case ep
merck offer improv growth prospect includ potenti upsid
consensu driven keytruda gardasil merck begin show oper
leverag key franchis beat expect older drug declin
fade pipelin progress encourag
bear case ep
bear case ep
keytruda gardasil disappoint drive ep forecast
competitor io trial show surprisingli strong result rel keytruda
overweight merck base upon solid
long-term growth prospect attract
see upsid consensu driven
oncolog franchis gardasil cancer
oper leverag start becom
visibl keytruda ramp older
pipelin option diseas beyond
oncolog specif vaccin hiv
come focu next year
keytruda sale trend trial
immuno-oncolog news flow
competitor roch azn
extern busi develop
us commerci govern price
competitor dataset newsflow
risk achiev price
upsid risk financi upsid pipelin
surpris competitor shortfal
downsid risk financi shortfal key
litig regulatori risk
price
price
price
compani data morgan stanley research estim thomson reuter valuat methodolog risk associ price target
referenc research report pleas contact client support follow us/canada hong kong latin
altern may contact invest repres morgan stanley research broadway attent research manag new
exhibit trade histor mean
sg sale
 sale
short-term invest
a/p accru liabil
total liabil s/e
chang work capit
oper
invest
net chang debt
financ
net chang cash
